Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1984 Apr;56(1):39–48.

B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine.

A Goday, H A Simmonds, G S Morris, L D Fairbanks
PMCID: PMC1535971  PMID: 6424986

Abstract

Enzyme inhibitors used to simulate the inherited immunodeficiency diseases, adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficiency, have been assessed in cultured human lymphocytes. Only 2'-deoxycoformycin (dCF) completely inhibited ADA in T and B cells at concentrations in excess of 5 microM. Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 8-amino guanosine (8-NH2GR) did not inhibit ADA or PNP completely at any concentration. Detailed metabolic experiments comparing viability and deoxynucleotide accumulation showed that B cell lines of malignant origin also accumulated high levels of dATP from 2'-deoxyadenosine (dAR), and dGTP from 2'-deoxyguanosine (dGR) as effectively as T cells--even without inhibitors, however, dAR reduced cell viability only when ADA was inhibited by dCF, whilst dGR was equally toxic with or without inhibitor, even to a line which accumulated no dGTP. These experiments indicate that cultured lymphocytes, using either EHNA or 8-NH2GR as enzyme inhibitor, are not valid models of the toxicity to the immune system in inherited ADA or PNP deficiency. They demonstrate that the ability to accumulate high levels of dATP or dGTP is not exclusive to T cells and that the in vitro toxicity of dAR or dGR could relate to the use of excess substrate and/or accumulation in different nucleotide, not deoxynucleotide pools.

Full text

PDF
39

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boss G. R., Thompson L. F., O'Connor R. D., Ziering R. W., Seegmiller J. E. Ecto-5'-nucleotidase deficiency: association with adenosine deaminase deficiency and nonassociation with deoxyadenosine toxicity. Clin Immunol Immunopathol. 1981 Apr;19(1):1–7. doi: 10.1016/0090-1229(81)90042-8. [DOI] [PubMed] [Google Scholar]
  2. Carson D. A., Kaye J., Matsumoto S., Seegmiller J. E., Thompson L. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A. 1979 May;76(5):2430–2433. doi: 10.1073/pnas.76.5.2430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carson D. A., Kaye J., Seegmiller J. E. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977 Dec;74(12):5677–5681. doi: 10.1073/pnas.74.12.5677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carson D. A., Kaye J., Wasson D. B. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J Immunol. 1981 Jan;126(1):348–352. [PubMed] [Google Scholar]
  5. Fairbanks L. D., Goday A., Morris G. S., Brolsma M. F., Simmonds H. A., Gibson T. Rapid determination of purine enzyme activity in intact and lysed cells using high-performance liquid chromatography with and without radiolabelled substrates. J Chromatogr. 1983 Sep 9;276(2):427–432. doi: 10.1016/s0378-4347(00)85112-9. [DOI] [PubMed] [Google Scholar]
  6. Gower W. R., Jr, Carr M. C., Ives D. H. Deoxyguanosine kinase. Distinct molecular forms in mitochondria and cytosol. J Biol Chem. 1979 Apr 10;254(7):2180–2183. [PubMed] [Google Scholar]
  7. Henderson J. F., Scott F. W., Lowe J. K. Toxicity of naturally occurring purine deoxyribonucleosides. Pharmacol Ther. 1980;8(3):573–604. doi: 10.1016/0163-7258(80)90077-7. [DOI] [PubMed] [Google Scholar]
  8. Hershfield M. S., Fetter J. E., Small W. C., Bagnara A. S., Williams S. R., Ullman B., Martin D. W., Jr, Wasson D. B., Carson D. A. Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells. J Biol Chem. 1982 Jun 10;257(11):6380–6386. [PubMed] [Google Scholar]
  9. Kazmers I. S., Mitchell B. S., Dadonna P. E., Wotring L. L., Townsend L. B., Kelley W. N. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts. Science. 1981 Dec 4;214(4525):1137–1139. doi: 10.1126/science.6795718. [DOI] [PubMed] [Google Scholar]
  10. Kefford R. F., Fox R. M. Purine deoxynucleoside toxicity in nondividing human lymphoid cells. Cancer Res. 1982 Jan;42(1):324–330. [PubMed] [Google Scholar]
  11. McGarrity G. J., Carson D. A. Adenosine phosphorylase-mediated nucleoside toxicity. Application towards the detection of mycoplasmal infection in mammalian cell cultures. Exp Cell Res. 1982 May;139(1):199–205. doi: 10.1016/0014-4827(82)90333-0. [DOI] [PubMed] [Google Scholar]
  12. Ochs U. H., Chen S. H., Ochs H. D., Osborne W. R., Scott C. R. Purine nucleoside phosphorylase deficiency: a molecular model for selective loss of T cell function. J Immunol. 1979 Jun;122(6):2424–2429. [PubMed] [Google Scholar]
  13. Simmonds H. A., Fairbanks L. D., Webster D. R., Rodeck C. H., Linch D. C., Levinsky R. J. Rapid prenatal diagnosis of adenosine deaminase deficiency and other purine disorders using foetal blood. Biosci Rep. 1983 Jan;3(1):31–38. doi: 10.1007/BF01121568. [DOI] [PubMed] [Google Scholar]
  14. Simmonds H. A., Sahota A., Potter C. F., Cameron J. S. Purine metabolism and immunodeficiency: urinary purine excretion as a diagnostic screening test in adenosine deaminase and purine nucleoside phosphorylase deficiency. Clin Sci Mol Med. 1978 May;54(5):579–584. doi: 10.1042/cs0540579. [DOI] [PubMed] [Google Scholar]
  15. Stoop J. W., Zegers B. J., Hendrickx G. F., van Heukelom L. H., Staal G. E., de Bree P. K., Wadman S. K., Ballieux R. E. Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency. N Engl J Med. 1977 Mar 24;296(12):651–655. doi: 10.1056/NEJM197703242961203. [DOI] [PubMed] [Google Scholar]
  16. Ullman B., Gudas L. J., Clift S. M., Martin D. W., Jr Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1074–1078. doi: 10.1073/pnas.76.3.1074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Webster A. D. Metabolic defects in immunodeficiency diseases. Clin Exp Immunol. 1982 Jul;49(1):1–10. [PMC free article] [PubMed] [Google Scholar]
  18. Wortmann R. L., Mitchell B. S., Edwards N. L., Fox I. H. Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. Proc Natl Acad Sci U S A. 1979 May;76(5):2434–2437. doi: 10.1073/pnas.76.5.2434. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES